Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

Targeting angiogenesis in glioblastoma (GBM) may improve patient outcome by normalizing tumor vasculature and improving delivery of chemotherapeutics and oxygen. Consequently, concomitant administration of small molecule inhibitors of the VEGF pathway will likely have a positive impact on chemoradia...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gerstner, Elizabeth R., Eichler, April F., Plotkin, Scott R., Drappatz, Jan, Doyle, Colin L., Xu, Lei, Duda, Dan G., Wen, Patrick Y., Jain, Rakesh K., Batchelor, Tracy T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4090923/
https://ncbi.nlm.nih.gov/pubmed/20821342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0390-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados